Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Medical Officer | March 06, 2025 | March 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date March 06, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 92,300 |
Reported balance
After 2025-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-06 · Grant · Acquired 92,300 · Balance 92,300 F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2025 Filed Mar 10, 2025 23:58 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 92,300 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000950170-25-036686 · ownership.xml · derivative · entry 1 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,300 Underlying: Common Stock · 92,300 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · derivative · entry 10 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 6,000 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · derivative · entry 9 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 6,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · derivative · entry 8 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 120,000 shares Expires 2030-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 552 | $30.05 | $16,587.60 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 7 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,043 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 6,000 | $30.05 | $180,300.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 6 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,595 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 6,000 | $8.04 | $48,240.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 5 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 6,000 | $30.05 | $180,300.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 4 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,595 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 6,000 | $15.78 | $94,680.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 3 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 12,000 | $30.05 | $360,600.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 2 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,595 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 01:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 12,000 | $18.66 | $223,920.00 |
DisclosureSEC source: 0000950170-24-012456 · ownership.xml · nonDerivative · entry 1 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-23-070014 · ownership.xml · derivative · entry 1 Kim Robert Young · CIK 0001971608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.